Published in Transl Cancer Res on December 01, 2016
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 10.89
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell (1997) 10.52
Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell (1996) 10.40
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 8.53
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev (1999) 6.34
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 6.31
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res (1994) 6.16
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev (1993) 6.02
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 5.76
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev (1993) 5.33
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol (1984) 4.83
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J (1991) 4.33
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 4.03
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet (1993) 3.85
Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A (1996) 3.78
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell (1994) 3.69
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer (2001) 3.61
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev (1996) 3.59
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene (1993) 3.43
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol (2000) 3.37
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37
Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature (1996) 3.37
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J (2001) 3.37
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol (2000) 3.25
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A (1999) 3.13
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J (2004) 3.10
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol (2002) 3.10
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08